Nasopharyngeal Cancer Program
Our mission is to provide comprehensive care and to conduct cutting edge research with a focus on translating discoveries from bench to bedside to help treat and cure individuals with nasopharyngeal cancer.
Call (650) 721-6509 for trial assistance
Our multidisciplinary group works together to care for patients throughout their treatment course for nasopharyngeal cancer, which is also known as nasopharynx cancer or nasopharyngeal carcinoma (NPC) of the head and neck. Our focus is on providing cutting-edge care for the best possible outcomes, including access to the latest diagnostics, treatments, and clinical trials, with a focus on each patient as an individual. The research from our group spans a spectrum from fundamental research to clinical applications. These research endeavors include basic science research to further our understanding of the underlying mechanisms of disease, fundamental engineering and bioengineering research to develop novel technologies for tumor imaging and treatment delivery, and development of clinical trials to investigate the latest targeted therapy and immunological approaches for the treatment of nasopharyngeal cancer patients. We are dedicated to providing the best possible care to each patient now… and helping to establish the standards of practice for the future.
Professor of Medicine and, by courtesy, of Otolaryngology - Head and Neck Surgery
Dr. Colevas is a medical oncologist with expertise in new drug development and multimodality treatment of head and neck cancers. He leads the Stanford head and neck cancer clinical research group. He is a principal investigator on numerous clinical trials, including both institutional and international studies enrolling NPC patients; these include trials that involve cellular immunotherapy, checkpoint inhibitors, and targeted small molecules.
Professor of Radiation Oncology and, by courtesy, of Otolaryngology - Head and Neck Surgery
Dr. Le is a radiation oncologist. Her research focuses on translating laboratory findings to the clinic and vice versa in head and neck cancer (HNC), specifically in the area of GalectinGalectin-1 and salivary gland stem cells. She is the Co-Director of the Radiation Biology Program of the Stanford Cancer Institute and the Chair of the Head and Neck Cancer Committee of the NRG Oncology Group. Her recent work includes exploration of EBV DNA as a biomarker for prognosis and treatment effect in patients with NPC, as well as harmonization of the EBV DNA assay for use in clinical trial in collaboration with Ben Pinsky.
Professor Otolaryngology - Head and Neck Surgery and, by courtesy, of Dermatology
Dr. Sunwoo’s research focuses on: (1) the immune response to head and neck cancer and to a cancer-causing population of cells within these tumors (2) a special lymphocyte population involved in innate immunity called natural killer (NK) cells; and (3) intra-tumor and inter-tumor heterogeneity. Much of his present bedside to bench work involves exploring mechanisms of sensitivity and resistance of tumors to immunotherapy in head and neck cancer patients.
Associate Professor of Radiation Oncology
Dr. Beadle is a radiation oncologist who specializes in the treatment of patients with head and neck cancer. She serves as the Director of the Head and Neck Radiation Oncology program at Stanford as well as the Director of Clinical Research for Radiation Oncology. She is dedicated to caring for each patient as an individual, providing the optimal care through treatment and survivorship, and her research is devoted to using advanced technologies to improve cancer outcomes and minimize side effects for patients diagnosed with NPC.
Assistant Professor, Radiation Oncology - Radiation Therapy
Dr. Gensheimer is a board-certified radiation oncologist who specializes in treatment of head and neck and lung cancers. He performs research on using computers to better interpret scan results and predict clinical outcomes. His research has been selected for several awards, including the ESMO Congress Merit Award, Best of ASTRO, and AAPM Science Council Session.
Professor of Otolaryngology - Head and Neck Surgery (Rhinology) and, by courtesy, of Neurosurgery
Dr. Hwang is Chief of the Division of Rhinology and Endoscopic Skull Base Surgery. He specializes in endoscopic approaches to tumors of the nasopharynx, sinuses and skull base. His research includes outcomes of surgical treatment of recurrent NPC, and management of chronic sinusitis complications of NPC treatment.
Associate Professor of Otolaryngology - Head & Neck Surgery (Rhinology) and, by courtesy, of Neurosurgery
Assistant Professor of Otolaryngology - Head and Neck Surgery and of Neurosurgery
Dr. Patel is an expert in advanced endoscopic sinus and skull base surgery. She treats patients with benign and malignant sinus and skull base tumors, as well as olfactory disorders.
Associate Professor of Pathology and Medicine
Dr. Pinsky’s research focuses on development and application of molecular assays for the diagnosis and management of infectious diseases. His lab developed the highly sensitive and specific assay of EBV DNA in human blood plasma which has been incorporated as a biomarker in several multi-institutional clinical trials of patients with NPC.
Associate Professor of Medicine and, by courtesy, of Dermatology
Dr. Weng’s basic research interest is immunotherapy for cancer, with two components: tumor specific targeting therapy and allogeneic transplant. He is currently working on new strategies to target patient-specific tumor using antibody along with effector cells. He is institutional principal investigator of a clinical trials for allogeneic T- cell immunotherapy for patients with EBV- related cancers, including NPC.
Professor of Pathology
Dr. West’s research includes identification of novel markers in tumors for diagnosis, prognosis and prediction of therapeutic response in cancer. He also using high through put sequencing approaches. He studies of driver mutations in head and neck cancers with a focus on salivary gland cancers and NPC.